

Media Release: Sydney, Australia. 29 May, 2014.

## PHEBRA LAUNCHES NEW PAIN RELIEF SPRAY

The Australian pharmaceutical company, Phebra, has announced the launch of a new pain relief spray for the Australian market.

Kriogese® is a fast acting topical anaesthetic skin coolant for pain relief.

“Kriogese® cools the skin and minimises pain,” Phebra’s Chief Executive Officer, Dr Mal Eutick, said today.

“Consisting of an ethyl chloride fine spray, Kriogese® leaves the skin cold and numb, with no residue.

“It’s proven to be an effective analgesic for controlling pain associated with immunisations, injections and blood sampling.

“Kriogese® can also be used for the management of minor sports injuries and can thus be used to prevent pain in children and adults alike.

“Phebra is proud of bringing Kriogese®, a highly effective spray for preventing a wide variety of pain, onto the Australian market.”

### ABOUT PHEBRA

Phebra is an Australian owned pharmaceutical company that develops manufactures and markets critical medicines in Australia, New Zealand, Asia, Canada and parts of Europe.

Phebra’s range of critical medicines covers a range of pharmaceuticals in important disease areas such as cystic fibrosis, antidotes, diagnostics, oncology and pain.



***At Phebra, we create critical medicines that save and improve lives.***

Phebra media contact:  
Richard Lenarduzzi. Premier Communications Group  
+61 411 254 390